Prostate cancer · 12 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cabozantinib monotherapy Variant #01 | — | R 90 983 | 28d | — | 11.0 mo | — | — | 1 |
Docetaxel, Enzalutamide, Prednisolone Variant #01 | — | R 12 977 | 21d | 9.5 mo | — | 14 | R 181 673 PFS proxy | 1 |
Cabazitaxel and Prednisone Variant #01 | — | R 9 372 | 21d | — | 14.5 mo | — | — | 7 |
Cabazitaxel and Prednisolone Variant #01 | — | R 7 502 | 21d | — | — | — | — | — |
Mitoxantrone and Hydrocortisone Variant #01 | — | R 5 071 | 21d | — | 12.3 mo | — | — | — |
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | — | ~13.8 mo | — | — | — |
Mitoxantrone and Prednisone Variant #01 | — | R 4 192 | 21d | — | 14.2 mo | — | — | 2 |
Docetaxel and Prednisone Variant #01 | — | R 4 155 | 42d | — | 21.2 mo | — | — | 13 |
Carboplatin, Docetaxel, Prednisone Variant #01 | — | R 3 934 | 28d | — | — | — | — | — |
Carboplatin and Docetaxel (DCb) Variant #01 | — | R 3 300 | 21d | ~4.7 mo | ~22.3 mo | ~7 | ~R 23 101 PFS proxy · indirect | 4 |
Docetaxel and Estramustine Variant #01 Partial | — | R 1 656 | 21d | — | 17.5 mo | — | — | 1 |
Docetaxel and Prednisolone Variant #01 | — | R 1 387 | 14d | 8.3 mo | 19.1 mo | 19 | R 26 352 PFS proxy | 3 |
12 of 12 regimens shown